Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a wholly owned managed AI agent platform, has announced that its representatives will participate in the IPAC-RS 2026 Nasal Innovation Forum. The event is scheduled to take place on Sept. 16-17, 2026, in Jersey City, New Jersey. The announcement comes as the company continues to advance its lead candidate, SPC-15, which utilizes a novel nose-to-brain delivery approach for the treatment of post-traumatic stress disorder (PTSD).
Eric Weisblum, CEO of Silo Pharma, expressed enthusiasm about the opportunity, stating that the forum provides a platform to engage with experts in nasal drug development. This engagement is part of Silo's ongoing efforts to refine and validate SPC-15's delivery system, which aims to target the brain directly via the nasal route, potentially improving therapeutic outcomes for patients suffering from PTSD.
The company also highlighted recent preclinical data demonstrating that the SPC-15 formulation and its delivery device met predefined specifications for assay, impurities, pH, and microbiological quality through a nine-month period. Additionally, six-month accelerated stability data were consistent and aligned with long-term data, reinforcing the product's robustness and shelf-life viability. Such stability is critical for regulatory approval and eventual commercialization.
PTSD is a debilitating condition that affects millions of individuals worldwide, often resulting from traumatic experiences. Current treatment options include psychotherapy and medications such as selective serotonin reuptake inhibitors (SSRIs), but many patients do not achieve adequate relief. Silo Pharma's SPC-15 represents a potential paradigm shift by leveraging the intranasal pathway for rapid and targeted drug delivery to the central nervous system, which may offer faster onset of action and reduced systemic side effects compared to traditional oral or injectable therapies.
The company's participation in the IPAC-RS forum is significant because it underscores Silo's commitment to advancing innovative drug delivery technologies. The forum brings together industry leaders, researchers, and regulatory experts to discuss challenges and opportunities in nasal and pulmonary drug delivery. By presenting its stability data and engaging with peers, Silo aims to gather insights that could further optimize SPC-15's development pathway.
Silo Pharma operates as a diversified biopharmaceutical and cryptocurrency treasury company, with a therapeutic focus on underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Its pipeline includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Research is conducted in collaboration with leading universities and laboratories, ensuring a strong scientific foundation.
The announcement of participation in the IPAC-RS 2026 Nasal Innovation Forum is a key milestone for Silo Pharma as it seeks to establish credibility and build relationships within the nasal drug delivery community. For investors and stakeholders, this move signals the company's proactive approach to regulatory engagement and its dedication to bringing SPC-15 to market. The positive stability data further bolster confidence in the product's technical feasibility, reducing some of the risks associated with drug development.
For the broader pharmaceutical industry, Silo's progress with SPC-15 highlights the growing interest in intranasal drug delivery as a viable alternative for central nervous system disorders. If successful, this approach could pave the way for similar treatments, expanding therapeutic options for patients and potentially lowering healthcare costs by improving drug efficacy and patient compliance.
As the forum approaches, Silo Pharma will likely provide further updates on its development timeline and regulatory strategy. The company's participation is a testament to its active role in shaping the future of nasal drug delivery.
